Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Noopept vs Semax
An educational, source-based comparison of Noopept and Semax — how each peptide works, what it's researched for, and what to know before going deeper.
Dipeptide-derived nootropic researched for memory and neuroprotection.
A synthetic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) derived from the endogenous nootropic cycloprolylglycine. Research suggests it potentiates AMPA receptor activity, increases BDNF and NGF expression, and provides antioxidant protection in neuronal tissue.
- Memory consolidation and retrieval
- Neuroprotection in ischemic injury
- Anxiety and emotional modulation
- Age-related cognitive decline
- • Approved in Russia; not FDA-approved in the US.
- • Generally well tolerated with few reported side effects.
A synthetic heptapeptide derived from ACTH(4-10). Research suggests it modulates BDNF and NGF expression, dopaminergic and serotonergic tone, and shows neuroprotective effects in ischemia models.
- BDNF/NGF upregulation
- Ischemic stroke recovery (clinical use in Russia)
- Attention and cognitive performance
- Anxiolytic-style effects
- • Approved as a medication in Russia; not FDA-approved in the US.
- • Most clinical literature is in Russian.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Noopept | Noopept neuroprotective effects in cerebral ischemia | Bulletin of Experimental Biology and Medicine | 2009 | Demonstrated protective effects against glutamate neurotoxicity in vitro. |
| Noopept | Noopept in mild cognitive impairment | Advances in Gerontology | 2012 | Improved cognitive scores in elderly patients with mild cognitive disorders. |
| Semax | Semax in the treatment of ischemic stroke | Zhurnal Nevrologii i Psikhiatrii | 2018 | Reported improved neurological recovery scores in acute ischemic stroke. |
| Semax | Semax and its analogs in neuroprotection | Molecular Neurobiology | 2020 | Review of neurotrophic and antioxidant mechanisms. |
Side-effect & safety grid
- Approved in Russia; not FDA-approved in the US.
- Generally well tolerated with few reported side effects.
- Approved as a medication in Russia; not FDA-approved in the US.
- Most clinical literature is in Russian.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Noopept vs Semax — Key differences
- Class: Noopept is classified as Nootropic · Neuroprotection, while Semax is Nootropic · Neuroprotection.
- Primary research focus: Noopept — memory consolidation and retrieval; Semax — bdnf/ngf upregulation.
- Tag: Cognition vs Cognition.